The new name reflects the growth of the company and its vision of creating security and transparency in global clinical studies
George Clinical, a leading, global order research institute (CRO), is pleased to announce that it is in Emerald Clinical Trials renamed. This strategic name change underlines the established position of the company as a committed, reliable, constant and flexible order research institute and at the same time reduces the global risks of clinical development by sound therapeutic and local expertise, which has been built for over 20 years.
Emerald Clinical Trials continues to focus on comprehensive services in all therapeutic areas that aim to change lives while innovations are promoted that contribute to the further development of global clinical research practices. With its strong track record in the therapeutic areas oncology and cardiac metabolic diseases (CRM), its proven expertise in the Asian-Pacific area and its global scientific management position, Emerald Clinical Trials is a highly differentiated clinical order research institute on the world stage. The large reach of the company – It works directly in 42 countries and about partnerships in 70 countries – ensures smooth implementation of clinical studies worldwide.
The new brand underlines the extraordinary work of Emerald Clinical Trials and emphasizes the width and depth of its experience for an even wider audience. It emphasizes a strong commitment for patients, customers and partners.
The great commitment of the company for customer orientation promotes long -term relationships based on trust, reliability and measurable success. Emerald’s ability to offer predictability in clinical studies is underlined by a success balance sheet for follow -up transactions, awards for outstanding services in the industry and a constant performance in the market launch of therapies.
“In the past two decades, Emerald Clinical Trials has focused on carrying out high-quality studies that combine a global range with a personal approach. Targeted, practical support he needs to minimize the risk of his clinical programs, “said Mary Gunn, CEO of Emerald Clinical Trials. “This exciting transformation strengthens our position as a trustworthy partner in clinical studies and at the same time confirms our commitment to our customers and our basic values.”
“We decided early on to work with an order research institute that is pursuing a flexible approach and offers solutions that are tailored to the specific requirements of each study, be it the acceleration of schedules, the adaptation of the study requirements or the efficient scaling of resources,” said Dr. Daniel Tillett, CEO of Race Oncology, a customer of Emerald. “Agility is of crucial importance for biopharma companies that need a partner who develops with them instead of braking them through bureaucratic inefficiency, and that is really a strength of Emerald Clinical Trials.”
Information on Emerald Clinical Trials Emerald Clinical Trials is a leading, global organization for clinical research, which looks after over 100 biotechnology companies and six of the ten leading pharmaceutical companies. The company, headquartered in Singapore, offers its customers comprehensive services in the field of clinical studies worldwide and offers solutions for all study phases. You can find more information at www.emeraldclinical.com.